W.K. Evans

652 total citations
31 papers, 538 citations indexed

About

W.K. Evans is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Economics and Econometrics. According to data from OpenAlex, W.K. Evans has authored 31 papers receiving a total of 538 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 10 papers in Economics and Econometrics. Recurrent topics in W.K. Evans's work include Lung Cancer Treatments and Mutations (11 papers), Economic and Financial Impacts of Cancer (8 papers) and Lung Cancer Research Studies (6 papers). W.K. Evans is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Economic and Financial Impacts of Cancer (8 papers) and Lung Cancer Research Studies (6 papers). W.K. Evans collaborates with scholars based in Canada, United States and Australia. W.K. Evans's co-authors include Joseph L. Pater, R. Feld, Pamela J. Goodwin, Ian D. Graham, George P. Browman, F. Shepherd, Kathleen I. Pritchard, D. Ian Hodson, E. Ann Mohide and James J. Rusthoven and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and CHEST Journal.

In The Last Decade

W.K. Evans

30 papers receiving 501 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
W.K. Evans Canada 10 253 200 160 99 62 31 538
Jaclyn Beca Canada 15 284 1.1× 204 1.0× 251 1.6× 83 0.8× 61 1.0× 58 691
Scott R. Berry Canada 13 281 1.1× 92 0.5× 132 0.8× 72 0.7× 65 1.0× 30 497
Dennis Cain United States 6 181 0.7× 66 0.3× 113 0.7× 109 1.1× 50 0.8× 9 834
Klazien Matter‐Walstra Switzerland 16 311 1.2× 178 0.9× 166 1.0× 56 0.6× 51 0.8× 40 580
Guy de Laroche France 12 206 0.8× 199 1.0× 60 0.4× 57 0.6× 127 2.0× 43 519
Simran Padam United States 7 266 1.1× 133 0.7× 161 1.0× 166 1.7× 39 0.6× 16 572
Molly Gabel United States 11 265 1.0× 97 0.5× 61 0.4× 68 0.7× 54 0.9× 17 480
C. Johnston United Kingdom 6 432 1.7× 136 0.7× 87 0.5× 89 0.9× 99 1.6× 9 701
Martijn Groot Netherlands 9 298 1.2× 110 0.6× 92 0.6× 39 0.4× 43 0.7× 12 507
G Gill Australia 8 445 1.8× 181 0.9× 102 0.6× 81 0.8× 214 3.5× 14 809

Countries citing papers authored by W.K. Evans

Since Specialization
Citations

This map shows the geographic impact of W.K. Evans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W.K. Evans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W.K. Evans more than expected).

Fields of papers citing papers by W.K. Evans

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W.K. Evans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W.K. Evans. The network helps show where W.K. Evans may publish in the future.

Co-authorship network of co-authors of W.K. Evans

This figure shows the co-authorship network connecting the top 25 collaborators of W.K. Evans. A scholar is included among the top collaborators of W.K. Evans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with W.K. Evans. W.K. Evans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cameron, Erin, et al.. (2019). OA09.07 Implementing an Opt-Out Approach to Smoking Cessation Referrals for Cancer Patients in Ontario, Canada. Journal of Thoracic Oncology. 14(10). S230–S231. 1 indexed citations
2.
Cameron, Erin, et al.. (2018). OA09.01 5As to 3As: Evolution of the Systematic Approach to Smoking Cessation in Ontario’s Regional Cancer Centres. Journal of Thoracic Oncology. 13(10). S340–S340. 1 indexed citations
3.
Mittmann, Nicole, H. Au, Christopher J. O’Callaghan, et al.. (2009). Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial. JNCI Journal of the National Cancer Institute. 101(17). 1182–1192. 122 indexed citations
4.
Maziak, Donna E., Gail Darling, Richard Inculet, et al.. (2008). A randomized controlled trial (RCT) of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) versus conventional imaging (CI) in staging potentially resectable non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 26(15_suppl). 7502–7502. 6 indexed citations
5.
Cheng, Susanna Y., W.K. Evans, Denise Stys‐Norman, & F. Shepherd. (2006). Chemotherapy for relapsed small cell lung cancer: a clinical practice guideline. 8 indexed citations
6.
Feld, R., et al.. (2006). Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a clinical practice guideline. 3 indexed citations
7.
Noble, Jason, et al.. (2006). Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a clinical practice guideline. 6 indexed citations
8.
Graham, Ian D., W.K. Evans, Alec O'connor, et al.. (2000). Canadian Oncologists and Clinical Practice Guidelines: A National Survey of Attitudes and Reported Use. Oncology. 59(4). 283–290. 34 indexed citations
9.
Evans, W.K.. (2000). An estimate of the cost of conducting phase II trials in lung cancer. Lung Cancer. 28(2). 85–95. 8 indexed citations
10.
11.
Browman, George P., E. Ann Mohide, Ian D. Graham, et al.. (1998). Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback.. Journal of Clinical Oncology. 16(3). 1226–1231. 104 indexed citations
12.
Coyle, Doug, Eva Grunfeld, Mark N. Levine, & W.K. Evans. (1997). PP15. Methods for conducting economic analysis of the long-term management of breast cancer: Description of two current Canadian studies. European Journal of Cancer. 33. S19–S20. 1 indexed citations
13.
Coyle, Doug, et al.. (1997). OP9. The cost of radiotherapy at an Ontario regional cancer centre. European Journal of Cancer. 33. S4–S4. 2 indexed citations
14.
Evans, W.K., et al.. (1997). PP20. Opportunities to reduce the cost of care for breast cancer (BC) in Canada. European Journal of Cancer. 33. S21–S22. 1 indexed citations
15.
16.
Evans, W.K., et al.. (1997). Use of vinorelbine in non-small-cell lung cancer. 7 indexed citations
17.
Evans, W.K., et al.. (1995). The cost of managing lung cancer in Canada.. PubMed. 9(11 Suppl). 147–53. 28 indexed citations
18.
Shepherd, Frances A., W.K. Evans, Paul E. Goss, et al.. (1992). Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer.. PubMed. 19(1 Suppl 1). 54–8. 10 indexed citations
19.
Goodwin, Pamela J., R. Feld, W.K. Evans, & Joseph L. Pater. (1988). Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer.. Journal of Clinical Oncology. 6(10). 1537–1547. 77 indexed citations
20.
Evans, W.K. & Richard J. Gralla. (1986). The Control of Nausea and Vomiting in Patients Receiving Cancer Chemotherapy. CHEST Journal. 89(4). 357S–359S. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jaclyn Beca Breakdown of academic impact, for papers by Scott R. Berry Breakdown of academic impact, for papers by Dennis Cain Breakdown of academic impact, for papers by Klazien Matter‐Walstra Breakdown of academic impact, for papers by Guy de Laroche Breakdown of academic impact, for papers by Simran Padam Breakdown of academic impact, for papers by Molly Gabel Breakdown of academic impact, for papers by C. Johnston Breakdown of academic impact, for papers by Martijn Groot Breakdown of academic impact, for papers by G Gill
Rankless by CCL
2026